Fulcrum to Merge with Slate Medicines in $350M All-Stock Deal, Pivoting to Migraine Pipeline
FULC sits 34% above its 52-week low of $2.83 on elevated volume (2.2× avg).
Summary
Fulcrum Therapeutics is merging with private biotech Slate Medicines in an all-stock deal that shifts the company's focus to migraine treatments. Fulcrum stockholders will own about 5% of the combined company, with Slate holders taking 95%. The deal includes a $245M oversubscribed private placement led by Frazier Life Sciences, and Fulcrum expects to pay a $270M cash dividend to its stockholders before closing. The combined company will operate as Slate Medicines under ticker SLTE, with cash runway into 2029. Slate's lead candidate SLTE-1009 targets PACAP and VIP for migraine, with Phase 1 data expected mid-2027. This follows Fulcrum's June restructuring after discontinuing its sickle cell program, leaving it as a shell seeking a strategic transaction. The merger provides a new pipeline and financing, but existing Fulcrum shareholders face significant dilution at 5% ownership. Closing is expected in Q4 2026.
At the time of this announcement, FULC was trading at $3.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $288.4M. The 52-week trading range was $2.83 to $15.74. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Benzinga.